Lai Shan Tam News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lai shan tam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lai Shan Tam Today - Breaking & Trending Today
Results highlighted a growing number of incident cases of asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, atopic dermatitis, and rheumatoid arthritis from 1990 to 2019. ....
Results highlighted a growing number of incident cases of asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, atopic dermatitis, and rheumatoid arthritis from 1990-2019. ....
A daily prednisolone dose of less than 5 mg was not associated with increased cardiovascular risk, whereas a dose of 5 mg or more doubled the risk for major adverse cardiovascular events. ....
E-Mail May 1, 2021 - Rheumatologists in Hong Kong joined hands to develop a set of consensus statements on COVID-19 vaccination for local adult patients with autoimmune rheumatic diseases. These timely statements would serve to be a guide for rheumatologists, other specialists, family physicians, specialty nurses, and the public regarding COVID-19 vaccination for patients with rheumatic diseases. Vaccination against SAR-CoV-2 is a new campaign and a high immunization rate is believed to be the key to end the pandemic. Currently, there are two COVID-19 vaccines available in Hong Kong the inactivated virus vaccine CoronaVac® (Sinovac) and the mRNA-based vaccine Comirnaty® (BioNTech/Fosun). However, due to the paucity of experience in patients with autoimmune rheumatic diseases, there are concerns from patients regarding the efficacy and safety of the new COVID-19 vaccines. This underscores the importance of input from rheumatologists in providing appropriate advice to pa ....
email article Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported. In a double-blind study that enrolled 110 patients, the number of patients who showed healing of erosions at 12 months was similar among those randomized to denosumab and those receiving placebo (18% vs 13%, P=0.45), but significantly more patients given denosumab experienced healing by 24 months (20% vs 6%, P=0.045), according to Lai-Shan Tam, MD, of the Chinese University of Hong Kong, and colleagues. [Denosumab] could be considered a treatment option for retarding bone damage progression independent of the disease activity control, the researchers wrote online in ....